Literature DB >> 12070661

Expression of ataxin-7 in CNS and non-CNS tissue of normal and SCA7 individuals.

Jenni Jonasson1, Anna-Lena Ström, Patricia Hart, Thomas Brännström, Lars Forsgren, Monica Holmberg.   

Abstract

Spinocerebellar ataxia type 7 (SCA7) is a neurodegenerative disorder primarily affecting the cerebellum, brain stem and retina. The disease is caused by an expanded polyglutamine tract in the protein ataxin-7. In this study we analyzed the expression pattern of ataxin-7 in CNS and non-CNS tissue from three SCA7 patients and age-matched controls. SCA7 is a rare autosomal dominant disorder, limiting the number of patients available for analysis. We therefore compiled data on ataxin-7 expression from all SCA7 patients (n=5) and controls (n=7) published to date, and compared with the results obtained in this study. Expression of ataxin-7 was found in neurons throughout the CNS and was highly abundant in Purkinje cells of the cerebellum, in regions of the hippocampus and in cerebral cortex. Ataxin-7 expression was not restricted to regions of pathology, and there were no apparent regional differences in ataxin-7 expression patterns between patients and controls. The subcellular distribution of ataxin-7 was primarily nuclear in all brain regions studied. In cerebellar Purkinje cells, however, differences in subcellular distribution of ataxin-7 were observed between patients and controls of different ages. Here we provide an increased understanding of the distribution of ataxin-7, and the possible implication of subcellular localization of this protein on disease pathology is discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12070661     DOI: 10.1007/s00401-001-0514-4

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  7 in total

1.  Differential degradation of full-length and cleaved ataxin-7 fragments in a novel stable inducible SCA7 model.

Authors:  Xin Yu; Abiodun Ajayi; Narasimha Rao Boga; Anna-Lena Ström
Journal:  J Mol Neurosci       Date:  2012-02-25       Impact factor: 3.444

Review 2.  The roles of proteolysis and nuclear localisation in the toxicity of the polyglutamine diseases. A review.

Authors:  R Walsh; E Storey; D Stefani; L Kelly; V Turnbull
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

Review 3.  Molecular Targets and Therapeutic Strategies in Spinocerebellar Ataxia Type 7.

Authors:  Anna Niewiadomska-Cimicka; Yvon Trottier
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

4.  Inhibition of autophagy via p53-mediated disruption of ULK1 in a SCA7 polyglutamine disease model.

Authors:  Xin Yu; Andrés Muñoz-Alarcón; Abiodun Ajayi; Kristin E Webling; Anne Steinhof; Ülo Langel; Anna-Lena Ström
Journal:  J Mol Neurosci       Date:  2013-04-18       Impact factor: 3.444

5.  Expanded ataxin-7 cause toxicity by inducing ROS production from NADPH oxidase complexes in a stable inducible Spinocerebellar ataxia type 7 (SCA7) model.

Authors:  Abiodun Ajayi; Xin Yu; Staffan Lindberg; Ulo Langel; Anna-Lena Ström
Journal:  BMC Neurosci       Date:  2012-07-24       Impact factor: 3.288

6.  Key Modulators of the Stress Granule Response TIA1, TDP-43, and G3BP1 Are Altered by Polyglutamine-Expanded ATXN7.

Authors:  Frida Niss; Laura Piñero-Paez; Wajiha Zaidi; Einar Hallberg; Anna-Lena Ström
Journal:  Mol Neurobiol       Date:  2022-06-10       Impact factor: 5.682

7.  Requirement for zebrafish ataxin-7 in differentiation of photoreceptors and cerebellar neurons.

Authors:  Constantin Yanicostas; Elisa Barbieri; Masahiko Hibi; Alexis Brice; Giovanni Stevanin; Nadia Soussi-Yanicostas
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.